1. Home
  2. GBR vs PRFX Comparison

GBR vs PRFX Comparison

Compare GBR & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Concept Energy Inc

GBR

New Concept Energy Inc

HOLD

Current Price

$0.69

Market Cap

3.2M

Sector

Energy

ML Signal

HOLD

Logo PainReform Ltd.

PRFX

PainReform Ltd.

HOLD

Current Price

$0.82

Market Cap

3.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBR
PRFX
Founded
1978
2007
Country
United States
Israel
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
3.1M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
GBR
PRFX
Price
$0.69
$0.82
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
69.0K
★ 232.6K
Earning Date
11-11-2026
09-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
★ $155,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 6.16
N/A
52 Week Low
$0.62
$0.58
52 Week High
$1.31
$5.39

Technical Indicators

Market Signals
Indicator
GBR
PRFX
Relative Strength Index (RSI) 44.19 39.06
Support Level $0.66 $0.58
Resistance Level $0.80 $1.28
Average True Range (ATR) 0.06 0.04
MACD -0.01 -0.01
Stochastic Oscillator 10.63 17.18

Price Performance

Historical Comparison
GBR
PRFX

About GBR New Concept Energy Inc

New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations.

About PRFX PainReform Ltd.

PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.

Share on Social Networks: